AbbVie Inc. $ABBV Shares Acquired by Colton Groome Financial Advisors LLC

Colton Groome Financial Advisors LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 50.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,274 shares of the company’s stock after purchasing an additional 2,767 shares during the quarter. Colton Groome Financial Advisors LLC’s holdings in AbbVie were worth $2,165,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Burk Holdings LLC bought a new stake in shares of AbbVie during the 2nd quarter worth about $30,000. Abound Financial LLC bought a new position in AbbVie in the 4th quarter valued at about $32,000. Merkkuri Wealth Advisors LLC acquired a new stake in AbbVie during the first quarter worth approximately $34,000. Marquette Asset Management LLC lifted its position in AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after acquiring an additional 48 shares during the last quarter. Finally, Phillip James Consulting Co. bought a new stake in shares of AbbVie during the fourth quarter worth approximately $36,000. 70.23% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.06% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive lymphoma trial results: AbbVie and Genmab reported that the Phase 3 EPCORE DLBCL-2 trial met its primary endpoint. Adding epcoritamab to R-CHOP produced a statistically significant and clinically meaningful improvement in progression-free survival for newly diagnosed diffuse large B-cell lymphoma patients. The companies plan to discuss the data with global regulators, strengthening AbbVie’s longer-term oncology growth prospects. AbbVie and Genmab EPCORE DLBCL-2 results
• Positive Sentiment: Higher analyst price target: Scotiabank raised its AbbVie target from $280 to $320 and reiterated a “sector outperform” rating, signaling confidence in the company’s earnings outlook and drug pipeline. Wall Street’s broader analyst view also remains favorable. Scotiabank raises AbbVie price target
• Neutral Sentiment: Upcoming third-quarter results: AbbVie is scheduled to report its third-quarter results later this month, with investors likely focused on Humira-related trends, newer immunology products, and whether the company can support its full-year outlook. Should You Buy AbbVie Stock Before Oct. 30?
• Neutral Sentiment: Additional pipeline and pricing developments: AbbVie’s FDA-approved Parkinson’s treatment and participation in a federal 340B rebate pilot could expand its commercial reach, although the longer-term financial impact remains uncertain.
• Negative Sentiment: Reduced third-quarter guidance: AbbVie now expects adjusted Q3 EPS of $3.73–$3.77, below the $3.85 consensus estimate. The company cited $216 million in acquired research, development, and milestone expenses; full-year adjusted EPS guidance was lowered by $0.11 to $13.76–$13.96. AbbVie updates 2026 EPS guidance

AbbVie Stock Up 0.6%

Shares of ABBV traded up $1.53 during trading hours on Tuesday, hitting $267.29. 1,479,835 shares of the company were exchanged, compared to its average volume of 6,420,333. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $269.39. The company has a market cap of $472.25 billion, a price-to-earnings ratio of 75.47, a P/E/G ratio of 1.19 and a beta of 0.24. The firm’s fifty day moving average is $258.05 and its 200 day moving average is $235.01.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio is 195.48%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ABBV shares. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and increased their target price for the stock from $235.00 to $300.00 in a research note on Thursday, August 13th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. HSBC lifted their target price on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Canaccord Genuity Group upped their price target on shares of AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, Piper Sandler lifted their price objective on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $273.82.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.